<DOC>
	<DOCNO>NCT02099201</DOCNO>
	<brief_summary>This single-center , double-blind , parallel-group , randomize , placebo-controlled , multiple-ascending oral dose study investigate safety , tolerability , pharmacokinetics , pharmacodynamics ACT-389949 healthy subject . Part A study evaluate safety tolerability follow day oral dose ACT-389949 9 day investigate ACT-389949 pharmacokinetics pharmacodynamics . Part B study evaluate safety tolerability ACT-389949 follow maximum two different oral dosing regimen : ACT-389949 give either every 3 day 13 day every 2 day 9 day ( 5 dos regimen ) . Part C study , require , provide additional information obtain Parts A B term safety , tolerability , pharmacokinetics , pharmacodynamics ACT-389949 .</brief_summary>
	<brief_title>Study Investigate Safety , Tolerability , Pharmacokinetics , Pharmacodynamics ACT-389949 Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Signed informed consent local language . Healthy Caucasian male subject female subject nonchildbearing potential . Men female partner childbearing potential must agree use 2 reliable method contraception first drug administration minimum 90 day end treatment . Male subject must agree donate sperm first drug administration 90 day end treatment . Nonsmokers , define never smoke achieve cessation ≥ 12 month prior screen . Body mass index 18.0 28.0 kg/m^2 ( inclusive ) screening . No clinically significant finding physical examination screening . Negative result urine alcohol drug screen screen Day −1 . Systolic blood pressure 100145 mmHg , diastolic blood pressure 5090 mmHg , pulse rate 4590 beat per minute ( inclusive ) measure screen . 12Lead electrocardiogram without clinically relevant abnormality screen . Body temperature 35.537.7 °C screen prior first dosing . Creactive protein ( CRP ) total differential white blood cell ( WBC ) count within local laboratory normal range screen Day 1 . Hematology , coagulation , clinical chemistry , urinalysis result ( total differential WBC CRP ) , deviate clinically relevant extent normal local laboratory range ( ) screening . Forced expiratory volume 1 second ( FEV1 ) ≥ 80 % predict , FEV1 / Forced vital capacity ≥ 70 % . Subjects must able provide adequate sputum follow induction hypertonic saline screening . Able communicate well investigator , local language , understand comply requirement study . Able stay unit entire duration require undertake study related procedure . Circumstances condition , , opinion investigator , may affect full participation study compliance protocol . History clinical evidence disease and/or existence surgical medical condition might interfere absorption , distribution , metabolism excretion study drug . Previous history fainting , collapse , syncope , orthostatic hypotension , vasovagal reaction . Veins unsuitable intravenous puncture either arm . Loss 250 mL blood blood donation , within 3 month prior screen . Known allergic reaction hypersensitivity excipient drug formulation ( ) . Previous exposure ACT389949 . Exposure lipopolysaccharide within last year . Treatment another investigational drug within 3 month prior screen participation 4 investigational drug study within 1 year prior screen . History clinical evidence alcoholism drug abuse within 3year period prior screen . Excessive caffeine consumption . Use regular medication therapy ( include vaccine ) overthecounter medication within 2 week prior first study drug administration 5 halflives medication , whichever longer . Positive result hepatitis serology , except vaccinated subject subject past resolve hepatitis , screen . Positive result human immunodeficiency virus serology screen . Vaccinations within previous 6 month foreign travel area within last 6 month infectious disease prevalent . Signs symptom suggestive infection within 2 week prior study screen screen dose . Signs respiratory tract infection within 2 week prior screen screen dose . History atopic allergy . Hay fever , within active season . Chronic disease include recur period flareups remission . Legal incapacity limit legal capacity screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>ACT-389949</keyword>
</DOC>